Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -227.37% is 171% below its 5-year average of -83.83%, near the low end of its 5-year range (-227.37%–-30.10%).
As of the fiscal period ended Tuesday, June 30, 2026. 48.40% below its 12-month average of -153.21%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -227.37%.
RETURN ON EQUITY (ROE)
-227.37%
RETURN ON EQUITY (ROE) AVG TTM
-153.21%
RETURN ON EQUITY (ROE) AVG 3Y
-108.51%
RETURN ON EQUITY (ROE) AVG 5Y
-83.83%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-48.40%
CURRENT VS 3Y AVG
-109.53%
CURRENT VS 5Y AVG
-171.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.87%
median of 380 covered companies
CURRENT VS SECTOR MEDIAN
-571.39%
vs the sector median at left
Bolt Biotherapeutics, Inc.
Market Cap
$6.72M
Return on Equity (ROE)
-227.37%
TTM Avg
-153.21%
3Y Avg
-108.51%
5Y Avg
-83.83%
Market Cap
$6.74M
Return on Equity (ROE)
-54.09%
TTM Avg
-388.62%
3Y Avg
-105.04%
5Y Avg
-44.72%
Market Cap
$6.76M
Return on Equity (ROE)
-108.00%
TTM Avg
-445.77%
3Y Avg
-254.63%
5Y Avg
-239.85%
Market Cap
$6.88M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
Market Cap
$6.44M
Return on Equity (ROE)
N/A
TTM Avg
-266.00%
3Y Avg
851.50%
5Y Avg
629.05%
Market Cap
$7.03M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$6.34M
Return on Equity (ROE)
-143.54%
TTM Avg
-132.34%
3Y Avg
-104.07%
5Y Avg
-91.90%
Market Cap
$6.10M
Return on Equity (ROE)
-304.78%
TTM Avg
-566.96%
3Y Avg
-321.57%
5Y Avg
-251.82%
Market Cap
$6.10M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.72M | -227.37% | -153.21% | -108.51% | -83.83% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -54.09% | -388.62% | -105.04% | -44.72% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -108.00% | -445.77% | -254.63% | -239.85% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -370.16% | -148.31% | -87.53% | -43.20% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | N/A | -266.00% | 851.50% | 629.05% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | -218.65% | -54.74% | -35.36% | -35.36% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -143.54% | -132.34% | -104.07% | -91.90% |
| Femasys Inc. (FEMY)vs › | $6.10M | -304.78% | -566.96% | -321.57% | -251.82% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -87.12% | -90.45% | -143.11% | -272.17% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 105.35% | 0.10% | -37.77% | -33.57% |
ROE
-227.4%
ROA
-71.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -227.37% |
| 2026-03-31 | -149.23% |
| 2025-12-31 | -125.92% |
| 2025-09-30 | -132.96% |
| 2025-06-30 | -130.56% |
| 2025-03-31 | -135.33% |
| 2024-12-31 | -110.35% |
| 2024-09-30 | -90.36% |
| 2024-06-30 | -77.06% |
| 2024-03-31 | -60.51% |
| 2023-12-31 | -61.38% |
| 2023-09-30 | -55.58% |
| 2023-06-30 | -54.03% |
| 2023-03-31 | -51.62% |
| 2022-12-31 | -51.37% |
| 2022-09-30 | -50.55% |
| 2022-06-30 | -46.59% |
| 2022-03-31 | -42.83% |
| 2021-12-31 | -39.42% |
| 2021-09-30 | -37.27% |
| 2021-06-30 | -30.10% |
| 2021-03-31 | -25.24% |
| 2020-06-30 | -67.36% |
